Subcutaneous RYBREVANT(amivantamab) delivers promising 45 percent overall response rate with median duration of response of 7.2 months in recurrent or metastatic head and neck cancer
Responses were rapid and durable, and tumour shrinkage was observed in 82…
NYSE Content Advisory: Pre-Market Update + Automakers await 5-year tariff relief extension
NEW YORK, Oct. 17, 2025 /PRNewswire/ -- The New York Stock Exchange…
Illumina constellation mapped read technology uncovers hard-to-see genomic insights in GeneDx pilot
Illumina's up-and-coming constellation innovation delivers accuracy, speed, and ease of use in…
NYSE Content Advisory: Pre-Market Update + HPE Unveils Strategic Business Priorities
NEW YORK, Oct. 16, 2025 /PRNewswire/ -- The New York Stock Exchange…
NYSE Content Advisory: Pre-Market Update + Embraer celebrates 25th listing anniversary
NEW YORK, Oct. 15, 2025 /PRNewswire/ -- The New York Stock Exchange…
NYSE Content Advisory: Pre-Market Update + Etsy transfers stock listing to NYSE
NEW YORK, Oct. 14, 2025 /PRNewswire/ -- The New York Stock Exchange…
NYSE Content Advisory: Pre-Market Update + LA Times Media Group takes step towards trading debut
NEW YORK, Oct. 13, 2025 /PRNewswire/ -- The New York Stock Exchange…
The Kia EV5 Delivers Authentic SUV Practicality in an Accessible Electric Package
The Kia EV5 is designed to support active lifestyles by providing maximum…
Alamar Biosciences Launches NULISAqpcr BD-pTau217 Assay: A Breakthrough in Non-Invasive, Brain-Specific Biomarker Detection for Alzheimer’s Disease Research
New Blood-Based Assay Delivers Unparalleled Sensitivity and Specificity to enable the next…
NYSE Content Advisory: Pre-Market update + Alliance Laundry Pops Nearly 13% in Trading Debut
NEW YORK, Oct. 10, 2025 /PRNewswire/ -- The New York Stock Exchange…